학술논문
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma
Document Type
Article
Author
Source
In Biology of Blood and Marrow Transplantation December 2015 21(12):2136-2140
Subject
Language
ISSN
1083-8791